Highlight
1. Patritumab deruxtecan (HER3-DXd) is a novel HER3-targeted antibody-drug conjugate showing durable antitumor activity in advanced NSCLC after prior platinum-based chemotherapy and immunotherapy.
2. In a phase II cohort of 47 patients without common EGFR mutations, the confirmed objective response rate was 27.7%, with a median progression-free survival of 5.5 months and overall survival of 15.2 months.
